Autopsy report · NCT01080638

Intracoronary Bolus Only Compared With Intravenous Bolus and 12-hours Infusion of Abciximab in Non-ST Elevation Myocardial Infarction.

“The study was terminated early due to a shortage of research and analytical personnel, which prevented the completion of the study as planned”

The sponsor’s own words in the registry.

Life of this trial

• Registered 6 months after it had already started.
• Ran for about 3 years 4 months before it stopped.
• 150 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 4

Sponsor

Seoul National University Hospital

Sponsor type

University, hospital or other

Conditions

Myocardial Infarction; Angioplasty

Interventions

glycoprotein IIb/IIIa inhibitor (abciximab)

Participants

150

Sites

1

Countries

South Korea

Trials that died the same way

• An Efficacy and Safety of Flomoxef Versus Cefepime in the Treatment of Participants With Urinary Tract Infections
  “Study was prematurely terminated due to administrative and strategic reasons” (84% match in meaning)
• Safety, Pharmacokinetics and Efficacy Study of QCC374 in PAH Patients
  “Study was terminated early for strategic reasons. Only Part I of the study was completed.” (84% match in meaning)
• Randomized Controlled Study to Incentivize Doctors for Appropriate Use of Medical Care in NL
  “The study was terminated due to logistical reasons” (83% match in meaning)
• SHR-1210 in Combination With BP102 and XELOX in Patient With Metastatic Colorectal Cancer
  “The study was terminated early due to company decision” (82% match in meaning)
• Therapeutic Exercise in Patients With Hemophilia
  “The Study was terminated due to lack of funding for continuing” (81% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.